Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S234500, C514S322000, C544S139000, C546S199000, C548S306100, C548S307400
Reexamination Certificate
active
07132438
ABSTRACT:
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.
REFERENCES:
patent: 3880874 (1975-04-01), Beard
patent: 3907700 (1975-09-01), Grier
patent: 4002623 (1977-01-01), Kadin
patent: 4011236 (1977-03-01), Grier
patent: 4874864 (1989-10-01), Schnur et al.
patent: 5654397 (1997-08-01), Cao et al.
patent: 5683999 (1997-11-01), Jadhav et al.
patent: 6130217 (2000-10-01), Arnold et al.
patent: 241684 (1986-12-01), None
patent: 63159861 (1988-07-01), None
patent: 11302177 (1999-11-01), None
patent: WO 93/23409 (1993-11-01), None
patent: WO 94/18212 (1994-08-01), None
patent: WO-94/22846 (1994-10-01), None
patent: WO 99/23091 (1999-05-01), None
patent: WO 00/20358 (2000-04-01), None
patent: WO 00/27819 (2000-05-01), None
patent: WO 00/75310 (2000-12-01), None
patent: WO 01/51641 (2001-07-01), None
patent: WO-01/070705 (2001-09-01), None
CA Registry No. 352333-82-5, Aug. 22, 2001.
CA Registry No. 350246-68-3, Aug. 3, 2001.
CA Registry No. 350046-32-1, Aug. 2, 2001.
CA Registry No. 342383-72-6, Jun. 19, 2001.
CA Registry No. 342383-71-5, Jun. 19, 2001.
CA Registry No. 339174-30-0, Jun. 1, 2001.
CA Registry No. 339154-79-9, Jun. 1, 2001.
CA Registry No. 337310-75-5, May 22, 2001.
CA Registry No. 333771-34-9, May 1, 2001.
CA Registry No. 333771-33-8, May 1, 2001.
CA Registry No. 332357-59-2, Apr. 25, 2001.
CA Registry No. 332357-58-1, Apr. 25, 2001.
CA Registry No. 331850-29-4, Apr. 19, 2001.
CA Registry No. 331840-06-3, Apr. 19, 2001.
CA Registry No. 330833-21-1, Apr. 11, 2001.
CA Registry No. 330833-03-9, Apr. 11, 200.
CA Registry No. 330830-15-4, Apr. 11, 2001.
CA Registry No. 330827-83-3, Apr. 11, 2001.
CA Registry No. 329220-92-0, Mar. 28, 2001.
CA Registry No. 328559-21-3, Mar. 25, 2001.
CA Registry No. 328559-20-2, Mar. 25, 2001.
CA Registry No. 326873-86-3, Mar. 13, 2001.
CA Registry No. 312309-96-9, Dec. 29, 2000.
CA Registry No. 302584-23-2, Nov. 13, 2000.
CA Registry No. 296799-22-9, Oct. 18, 2000.
CA Registry No. 296793-49-2, Oct. 18, 2000.
CA Registry No. 292613-16-2, Oct. 4, 2000.
CA Registry No. 292613-15-1, Oct. 4, 2000.
CA Registry No. 292613-14-0, Oct. 4, 2000.
CA Registry No. 292613-13-9, Oct. 4, 2000.
CA Registry No. 292613-12-8, Oct. 4, 2000.
CA Registry No. 292613-11-7, Oct. 4, 2000.
CA Registry No. 62553-67-7, Nov. 16, 1984.
Da Settimo et al., CA 118:182981, 1993.
Vitkevich et al., CA 55:87457, 1961.
Rao et al., CA 110:212706, 1989.
Sakamoto et al., CA 107:165339, 1987.
Rastogi et al., CA 92:215343, 1980.
Schulze et al., CA 79:92102, 1973.
VanAllan et al., CA 69:77169, 1968.
Golub et al., Science, vol. 286, Oct. 15, 1999, pp. 531-537.
Auron, P., “The Interleukin 1 Receptor: Ligand Interactions and Signal Transduction,” Cytokine & Growth Fac. Rev, 1998, vol. 9, No. 3/4, pp. 221-237, GB.
Buscemi et al., “Heterocyclic Photoarrangements. Photochemical Behaviour of Some 3,5-Disubstituted 1,2,4-Oxadiazoles in Methanol at 254 nm,” J. of Heterocyclic Chem., 1988, vol. 25, No. 3, pp. 931-935, US.
Cao et al., “IRAK: A Kinase Associated with the Interleukin-1 Receptor,” Science, Feb. 23, 1996, vol. 271, pp. 1128-1131, US.
Cao et al., “TRAF is a Signal Transducer for Interleukin-1,” Nature, Oct. 3, 1996, vol. 383, pp. 383-446, US.
Dinarello, C., “Interleukin-1,” Cytokine & Growth Fac. Rev., 1997, vol. 8, No. 4, pp. 253-265, GB.
Heyer, D., “NPY5 Antagonists for Obesity,” Aug. 6, 2001, MedChem Gordon Research Conference 2001, Power Point Presentation Slides.
Kanakaraj et al., “Defective Interleukin (IL)-18-mediated Natural Killer and T Helper Cell Type 1 Responses in IL-1 Receptor-associated Kinase (IRAK)-deficient Mice,” J. Exp. Med., Apr. 5, 1999, vol. 189, No. 7, pp. 1129-1138, The Rockefeller Univ. Press, US.
Moffett et al., “Antiulcer Agents. p-Aminobenzamido Aromatic Compounds,” J. of Medicinal Chem., 1971, vol. 14, No. 10, pp. 963-968, US.
Muzio et al., “IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signalling,” Science, Nov. 28, 1997, vol. 278, pp. 1612-1615, US.
O'Neill et al., “Signal Transduction Pathways Activated by the IL-1 Receptor Family: Ancient Signaling Machinery in Mammals, Insects and Plants,” J. of Leukocyte Bio., Jun. 1998, vol. 63, pp. 650-657, US.
O'Neill, L., “The Toll/Interleukin-1 Receptor Domain: a Molecular Switch for Inflammation and Hose Defence,” Biochemical Society Transactions, 2000, vol. 28, Pt. 5, pp. 557-563, Trinity College, Ireland.
Wesche et al., “IRAK-M is a Novel Member of the Pelle/Interleukin-1 Receptor-associated Kinase (IRAK) Family,” J. of Bio. Chem., Jul. 2, 1999, vol. 274, No. 27, pp. 19403-19410, US.
Yang et al., “Signaling Events Induced by Lipopolysaccharide-activated Toll-like Receptor 2,” J. of Immunology, 1999, vol. 163, pp. 639-643, US.
Frenkel Alexander David
Lively Sarah Elizabeth
Powers Jay P.
Smith Andrew
Sun Daqing
Jones Day
Stockton Laura L.
LandOfFree
Benzimidazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698532